Development of an Opioid Withdrawal Clinical Outcome Assessment

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Maryland, Baltimore

About this trial

Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification. This project will develop and validate a clinical outcome assessment (COA) for opioid withdrawal,essential for standardizing withdrawal mitigation strategies and establishing best practices. In line with the FDA's drug development tool qualification guidelines, our methodological process will involve conducting focus groups with persons with lived experience of opioid withdrawal for concept elicitation, refining these concepts through cognitive interviews, and conducting construct and longitudinal validations of the new assessment in laboratory settings and across diverse treatment contexts.

Eligibility criteria

Qualifiers

Past year opioid use disorder, determined by (a) enrollment in current treatment for opioid use disorder and/or (b) an opioid-positive saliva test.

Fluent in English

Has experience with opioid withdrawal at least once in the past 30 days

Disqualifiers

Unable to provide informed consent due to cognitive impairment

Being pregnant or breastfeeding

History of psychosis or mania as determined by the MINI

Exhibiting suicidal behavior in the past 30 days as determined by the C-SSRS

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

30 Participants
are grouped into 2 trial groups

Sponsors and collaborators

University of Maryland, Baltimore

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator